Literature Collection

Understanding the impact of medications for opioid use disorder on health related quality of life (QOL) may help to explain why few individuals with legal involvement remain in treatment, specifically those receiving opioid antagonists. QOL is an established predictor of treatment retention and has been shown to improve with some treatment for opioid use disorder. Yet limited research has examined QOL with opioid antagonists. We examined the impact of extended release naltrexone (XR-NTX) on QOL and retention in treatment in a randomized, multi-site trial of individuals with legal involvement. Methods: The participants were 308 community-dwelling adults with current or recent legal involvement with opioid dependence at five site across United States. They were randomized to receive XR-NTX or treatment as usual for 6 months. QOL was measured every 2 weeks using Euro QOL individual items, summary index score, and health state today metric. Results: No significant difference in QOL scores were observed between the two groups at the completion of active treatment or on follow up at 52 and 78 weeks. There were no time effects of treatment on scores. Contrary to expectation, baseline and average QOL did not predict retention in treatment. Conclusion: In contrast to prior research, our findings did not demonstrate significant changes (improvements or decreases) in QOL associated with XR-NTX treatment. Clinicians may consider that individuals receiving XR-NTX may not experience changes in perceived well-being in response to treatment and consider discussing with patients that they may not necessarily perceive improvement in their QOL. This may help to ground patient's expectations about the effects of treatment and potentially reduce attrition from treatment with opioid antagonists.

PURPOSE: Timely and integrated palliative care is crucial for patients with metastatic breast cancer. However, data on models of integration are scarce. We aimed to evaluate the impact of the integration of an embedded model of palliative care in a multidisciplinary breast unit on important goals of care and to characterize different patterns of integration (palliative predominant, oncology predominant or concurrent). METHODS: Single-center, retrospective, observational cohort study including all patients with metastatic breast cancer followed by the palliative and oncology teams from a 12-month period before (pre-implementation) and after (post-implementation) of an embedded model of integration of palliative care. We analyzed early integration, 1-year survival rate, survival and different patterns of coordination of palliative care and oncology (the oncology-predominant pattern, the palliative care-predominant pattern and the concurrent integrated care pattern). RESULTS: From April 2020 to April 2022, a total of 145 patients were included in the analysis: all female, median age of 63.5 years, 20.7% with triple negative disease. Post-implementation, early referrals significantly increased (35.3 to 61.3%, p < 0.01), 1-year survival rate (40.1% vs 40.7%) and survival time were similar (9.2 months vs 9.9 months). An integrated pattern of care with concurrent palliative and oncology appointments was significantly more frequent (30% vs 61%, p < 0.01). When compared to the other patterns, the concurrent pattern was associated to a median of 4 months longer survival (p < 0.01). CONCLUSIONS: The incorporation of an embedded model of palliative care was associated with earlier referrals and translated into better outcomes for patients with metastatic breast cancer.

Psychoactive substance use among children in Afghanistan is an issue of concern. Somewhere around 300,000 children in the country have been exposed to opioids that either parents directly provided to them or by passive exposure. Evidence-based and culturally appropriate drug prevention and treatment programs are needed for children and families. The goals of this study were to: (1) examine lifetime psychoactive substance use in girls and boys at treatment entry; and (2) examine differential changes in substance use during and following treatment between girls and boys. Children ages 10-17 years old entering residential treatment were administered the Alcohol, Smoking and Substance Involvement Screening Test for Youth (ASSIST-Y) at pre- and post-treatment, and at three-month follow-up. Residential treatment was 45 days for children and 180 days for adolescents and consisted of a comprehensive psychosocial intervention that included education, life skills, individual and group counseling and, for older adolescents, vocational skills such as embroidery and tailoring. Girls and boys were significantly different regarding lifetime use of five substances at treatment entry, with girls less likely than boys to have used tobacco, cannabis, stimulants, and alcohol, and girls more likely than boys to have used sedatives. Differences between boys and girls were found for past-three-month use of four substances at treatment entry, with girls entering treatment with higher past-three-month use of opioids and sedatives, and boys with higher past-three-month use of tobacco, cannabis, and alcohol. Change over the course of treatment showed a general decline for both girls and boys in the use of these substances. Girls and boys in Afghanistan come to treatment with different substance use histories and differences in past-three-month use. Treatment of children for substance use problems must be sensitive to possible differences between girls and boys in substance use history.